Novo Nordisk’s Sogroya (somapacitan-beco) Receives the US FDA Approval for Adult Growth Hormone Deficiency

 Novo Nordisk’s Sogroya (somapacitan-beco) Receives the US FDA Approval for Adult Growth Hormone Deficiency

Novo Nordisk Resumes P-III Study of Concizumab for Patients with Hemophilia A and B

Shots:

  • The approval is based on REAL 1 study assessing Sogroya (10 mg/ 1.5 mL (6.7 mg/mL) vs PBO for 35wks. in adults patients with growth hormone deficiency
  • The US FDA ahs approved the BLA of the therapy for the replacement of endogenous growth hormone in adults with GHD
  • Sogroya is a prescription medicine containing GH and is used to treat adults who do not make enough growth hormone. Efficacy and safety in children are not known

Click here ­to­ read full press release/ article | Ref: Businessnewswire | Image: Businessnewswire

Parag Narang

Parag Narang is a Digital Marketing Associate at PharmaShots, a division of Octavus Consulting. He manages the digital marketing as well as the designing ideas for PharmaShots. He has a degree in Bachelor of Business Administration along with Post Graduate Program in Management (Marketing). Parag manages all the social media handles very well since he has a good experience in Marketing & Sales.

Related post